CALLIDITAS THERAPEUTICS AB FDA Approval NDA 215935

NDA 215935

CALLIDITAS THERAPEUTICS AB

FDA Drug Application

Application #215935

Documents

Label2021-12-20
Letter2021-12-21

Application Sponsors

NDA 215935CALLIDITAS THERAPEUTICS AB

Marketing Status

Prescription001

Application Products

001CAPSULE, DELAYED RELEASE;ORAL4MG2TARPEYOBUDESONIDE

FDA Submissions

TYPE 5; Type 5 - New Formulation or New ManufacturerORIG1AP2021-12-15PRIORITY

Submissions Property Types

ORIG1Orphan5

TE Codes

001PrescriptionTBD

CDER Filings

CALLIDITAS THERAPEUTICS AB
cder:Array
(
    [0] => Array
        (
            [ApplNo] => 215935
            [companyName] => CALLIDITAS THERAPEUTICS AB
            [docInserts] => ["",""]
            [products] => [{"drugName":"TARPEYO","activeIngredients":"BUDESONIDE","strength":"4MG","dosageForm":"CAPSULE, DELAYED RELEASE;ORAL","marketingStatus":"Prescription","te":"","rld":"TBD","rs":"No"}]
            [labels] => [{"actionDate":"12\/15\/2021","submission":"ORIG-1","supplementCategories":"Approval","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2021\\\/215935s000lbl.pdf\"}]","notes":""}]
            [originalApprovals] => [{"actionDate":"12\/15\/2021","submission":"ORIG-1","actionType":"Approval","submissionClassification":"Type 5 - New Formulation or New Manufacturer","reviewPriority":"PRIORITY; Orphan","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2021\\\/215935s000lbl.pdf\"},{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2021\\\/215935Orig1s000ltr.pdf\"}]","notes":">"}]
            [supplements] => 
            [actionDate] => 2021-12-15
        )

)

© 2022 FDA.report
This site is not affiliated with or endorsed by the FDA.